Radiotherapy in COVID-19

Phase 1

• Conditions: COVID-19 pneumonia.; Pneumonia due to SARS-associated coronavirus; J12.81

• Registration Number: IRCT20200509047366N1
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 18 May 2020

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

Confirmed COVID-19 diagnosis ( PCR or serologic)
Presence of pulmonary involvement ( defined by P/F ratio or NIV need)
Less than 3 days since the onset of ARDS
Age > 60 years
? IL-6 ( if available)
? CRP

Exclusion Criteria

Lack of informed consent
Inability to transfer to the radiation unit
Hemodynamic instability
Septic shock and organ dysfunction
Severe ARDS P/F ratio = 100 mmHg
History of cardiac failure
Contraindications to radiation

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Increase in arterial oxygen pressure. Timepoint: day 1,2,3,4,5,6,7,14,21,28 post treatment. Method of measurement: Blood sample.

Secondary Outcome Measures

Name	Time	Method
P/F ratio. Timepoint: day 1,2,3,4,5,6,7,21,28. Method of measurement: Blood gas analysis.;Hs-CRP. Timepoint: day 1,2,3,4,5,6,7,21,28. Method of measurement: blood sample.;IL-6 serum level. Timepoint: day 1,4,7,21,28. Method of measurement: blood sample.;ESR. Timepoint: day 1,2,3,4,5,6,7,14,21,28. Method of measurement: Blood sample.